Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer

Clinical Cancer Research

Volumn 12, Issue 3 II, 2006, Pages

  Kim, Hyun Jung ^a   Cui, Xiaojiang ^a   Hilsenbeck, Susan G ^a   Lee, Adrian V ^a,b   Dowsett, Mitch ^c   Pritchard, Kathleen ^c   Come, Steven ^c   Ingle, James ^c   Paik, Soonmyung ^c   Buzdar, Aman ^c   Arteaga, Carlos ^c  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B;

BREAST CANCER; CANCER CELL CULTURE; CONFERENCE PAPER; DOWN REGULATION; HUMAN; LIGAND BINDING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CLINICAL TRIALS; FEMALE; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; UP-REGULATION;

EID: 32944475015     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2128     Document Type: Conference Paper

References (48)

1. Campos SM, Winer EP. Hormonal therapy in postmenopausal women with breast cancer. Oncology 2003;64:289-99.
2. Baum M, Buzdar A. The current status of aromatase inhibitors in the management of breast cancer. Surg Clin North Am 2003;83:973-94.
3. Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 2003;8:335-41.
4. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
5. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-9.
6. Ravdin PM, Green S, Dorr TM, et al. I. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992;10:1284-91.
7. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000;89:111-7.
8. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-16
9. Dowsett M, Harper-Wynne C, Boeddinghaus I, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001;61:8452-8.
10. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10.
11. Dowsett M. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003;82:37.
12. Horwitz KB, McGuire WL, Pearson OH, Segaloff A. Predicting response to endocrine therapy in human breast cancer. Science 1975;189:726-7.
13. McGuire WL. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 1978;5:428-33.
14. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-53.
15. Osborne CK, Yochmowitz MG, Knight WA, III, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980;46:2884-8.
16. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
17. Balleine RL, Earl MJ, Greenberg ML, Clarke CL. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer 1999;79:1564-71.
18. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 2000;53:688-96.
19. Huang HJ, Neven P, Drijkoningen M, et al. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Breast Cancer Res Treat 2005;91:81-7.
20. Arpino G, Weiss H, Lee A, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: Correlation with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. In press 2005.
21. Hull DF, Clark GM, Osborne CK, Chamness GC, Knight WAI, McGuire WL. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983;43:413-6.
22. Potter JD, Cerhan JR, Sellers TA, et al. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev 1995;4:319-26.
23. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002;76:27-36.
24. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004;96:218-28.
25. Cui X, Zhang P, Deng W, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003;17:575-88.
26. Cormier EM, Wolf MF, Jordan VC. Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growth. Cancer Res 1989;49:576-80.
27. Lee AV, Weng CN, Jackson JG, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 1997;152:39-47.
28. Petz LN, Ziegler YS, Schultz JR, Nardulli AM. Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site. Mol Endocrinol 2004;18:521-32
29. Torres-Arzayus MI, De Mora JF, Yuan J, et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004;6:263-74.
30. Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 2005;123:541-6.
31. Dixon JM, Jackson J, Hills M, et al. Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. Eur J Cancer 2004;40:2742-7.
32. Bamberger AM, Milde-Langosch K, Schulte HM, Loning T. Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Horm Res 2000;54:32-7.
33. Taucher S, Rudas M, Mader RM, et al. Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer 2003;98:2547-53.
34. Huang HJ, Neven P, Drijkoningen M, et al. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 2005; 58:611-6.
35. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004;3:379-98.
36. Shi W, Zhang X, Pintilie M, et al. Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Int J Cancer 2003;104:195-203.
37. Perren A, Weng LP, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999;155:1253-60.
38. Garcia JM, Silva JM, Dominguez G, et al. Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 1999; 57:237-43.
39. Schorry EK, Oppenheimer SG, Saal HM. Valproate embryopathy: clinical and cognitive profile in 5 siblings. Am J Med Genet A 2005;133:202-6.
40. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81.
41. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;3:772-5.
42. Horwitz KB, McGuire WL, Pearson OH, Segaloff A. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 1975;189:726-7.
43. Horwitz KB, McGuire WL. Estrogen control of progesteone receptor in human breast cancer. J Biol Chem 1978;253:2223-8.
44. Bloom ND, Tobin EH, Schreibman B, Degenshein GA. The role of progesterone receptors in the management of advanced breast cancer. Cancer 1980;45:2992-7.
45. Lapidus RG, Ferguson AT, Ottaviano YL, et al. Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 1996;2:805-10.
46. Tomlinson IP, Nicolai H, Solomon E, Bodmer WF. The frequency and mechanism of loss of heterozygosity on chromosome 11q in breast cancer. J Pathol 1996;180:38-43.
47. Winqvist R, Hampton GM, Mannermaa A, et al. Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res 1995;55:2660-4.
48. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10:331-6S.